Apellis Pharmaceuticals, Inc. (APLS) Social Stream
Apellis Pharmaceuticals Inc (APLS) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Apellis Pharmaceuticals Inc.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-10 | 12 | $116 | $28 | $68.307 | $58.34 | 17.08% |
| 2021-11-12 | 12 | $116 | $28 | $67.23 | $58.34 | 15.24% |
| 2021-11-17 | 11 | $116 | $28 | $67.692 | $58.34 | 16.03% |
| 2021-11-24 | 12 | $116 | $28 | $68.076 | $58.34 | 16.69% |
| 2021-11-29 | 12 | $116 | $28 | $67.615 | $58.34 | 15.9% |
| 2021-12-15 | 13 | $116 | $28 | $68.785 | $58.34 | 17.9% |
| 2022-01-05 | 13 | $116 | $28 | $69 | $58.34 | 18.27% |
| 2022-01-11 | 13 | $112 | $28 | $69.142 | $58.34 | 18.52% |
| 2022-01-26 | 13 | $112 | $34 | $69.571 | $58.34 | 19.25% |
| 2022-03-02 | 13 | $114 | $34 | $69.714 | $58.34 | 19.5% |
| 2022-03-16 | 13 | $114 | $34 | $69.5 | $58.34 | 19.13% |
| 2022-03-17 | 13 | $114 | $34 | $70.428 | $58.34 | 20.72% |
| 2022-03-22 | 12 | $114 | $34 | $70 | $58.34 | 19.99% |
The Trend in the Analyst Price Target
APLS's average price target has moved down $4.33 over the prior 38 weeks.
Over the past 49 weeks, APLS's average upside potential has been 52.49%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-17 | 11 | 116 | 28 | 67.750 | 45.12 | 50.16% |
| 2021-11-17 | 12 | 116 | 28 | 67.692 | 45.12 | 50.03% |
| 2021-11-29 | 12 | 116 | 28 | 67.615 | 42.86 | 57.76% |
| 2022-01-11 | 13 | 112 | 28 | 69.142 | 41.15 | 68.02% |
| 2022-01-25 | 13 | 112 | 34 | 69.571 | 39.67 | 75.37% |
APLS Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.33 | 10 | 0 | 2 | 0 | 0 | 12 |
The Trend in the Broker Recommendations
APLS's average broker recommendation rating improved by 0.39 over the prior 24 months.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- APLS has a lower variance in analysts' estimates than -1526.45% of all US stocks.
- In terms of how Apellis Pharmaceuticals Inc fares relative to stocks in the mid market cap category, note that its number of analysts covering the stock is greater than 1563.66% of that group.
- Apellis Pharmaceuticals Inc's upside potential (average analyst target price relative to current price) is greater than 166.01% of Pharmaceutical Products stocks.
- Apellis Pharmaceuticals Inc's average analyst price target is greater than 1338.11% of Pharmaceutical Products stocks.
Stocks similar to Apellis Pharmaceuticals Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are ANAB, AMTI, and AMRX.
Make investment decisions regarding APLS using the data that counts. Try POWR Ratings for free.